The University Medical Center Utrecht (UMCU) is a leading international academic medical centre with over 1,100 beds and close to 12,000 employees. The UMCU Wilhelmina Children’s Hospital is one of the oldest and largest Children’s Hospitals in the Netherlands, and is closely associated with the Princess Maxima Center for Paediatric Oncology. The UMCU is part of Utrecht University, which is 74th overall in The World University Rankings 2019. Two of the six strategic research programs of the UMCU are Child Health and Infection & Immunity.
UMC Utrecht will be involved in clinical patient recruitment of febrile patients. UMC Utrecht and Newcastle University will lead the recruitment of immunocompromised patients in DIAMONDS (pediatric oncology patients, stem cell transplant patients) and contribute to the recruitment of other categories including rheumatologic, inflammatory and autoinflammatory diseases. The Children’s Hospital has a large Paediatric Intensive Care Unit, and a large Paediatric Rheumatology Department with international leading roles in idiopathic juvenile arthritis and autoinflammatory disease. The hospital provides the infectious disease clinical service in the Princess Maxima Center for Paediatric Oncology.
Michiel van der Flier MD PhD is a consultant in Paediatric Infectious Diseases and Immunology and performs translational research into the host response in severe childhood infections. He participated in EUCLIDS and PERFORM and coordinated the clinical network PedBIG in these studies in Dutch Hospitals – www.pedbig.nl. DIAMONDS co-investigators are Prof Wim Tissing MD PhD (consultant in paediatric oncology and principal Investigator in supportive care research at the Princess Maxima Center for Paediatric) and Bas Vastert MD PhD (consultant in paediatric rheumatology, co-head of the paediatric rheumatology research group) and Tom Wolfs MD PhD (consultant in paediatric infectious diseases and immunology).See all Partners
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 848196